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Abstract
Background: Myocardium damage during Chagas’ disease results from the immunological imbalance between pro- and
production of anti-inflammatory cytokines and has been explained based on the Th1–Th2 dichotomy and regulatory T cell
activity. Recently, we demonstrated that IL-17 produced during experimental T. cruzi infection regulates Th1 cells
differentiation and parasite induced myocarditis. Here, we investigated the role of IL-17 and regulatory T cell during human
Chagas’ disease.
Methodology/Principal Findings: First, we observed CD4+IL-17+ T cells in culture of peripheral blood mononuclear cells
(PBMC) from Chagas’ disease patients and we evaluated Th1, Th2, Th17 cytokine profile production in the PBMC cells from
Chagas’ disease patients (cardiomyopathy-free, and with mild, moderate or severe cardiomyopathy) cultured with T. cruzi
antigen. Cultures of PBMC from patients with moderate and severe cardiomyopathy produced high levels of TNF-a, IFN-c
and low levels of IL-10, when compared to mild cardiomyopathy or cardiomyopathy-free patients. Flow cytometry analysis
showed higher CD4+IL-17+ cells in PBMC cultured from patients without or with mild cardiomyopathy, in comparison to
patients with moderate or severe cardiomyopathy. We then analyzed the presence and function of regulatory T cells in all
patients. All groups of Chagas’ disease patients presented the same frequency of CD4+CD25+ regulatory T cells. However,
CD4+CD25+ T cells from patients with mild cardiomyopathy or cardiomyopathy-free showed higher suppressive activity
than those with moderate and severe cardiomyopathy. IFN-c levels during chronic Chagas’ disease are inversely correlated
to the LVEF (P = 0.007, r =20.614), while regulatory T cell activity is directly correlated with LVEF (P = 0.022, r = 0.500).
Conclusion/Significance: These results indicate that reduced production of the cytokines IL-10 and IL-17 in association with
high levels of IFN-c and TNF-a is correlated with the severity of the Chagas’ disease cardiomyopathy, and the immunological
imbalance observed may be causally related with deficient suppressor activity of regulatory T cells that controls myocardial
inflammation.
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Introduction
At the present time, about 7.7 million people are infected and
28 million are at risk of being infected with Trypanosoma cruzi in
Central and South America [1–3]. This hemoflagellate protozoan
is the etiological agent of Chagas’ disease. Most of the infected
individuals remain asymptomatic during chronic infection (60–
70%), characterizing the indeterminate form of the disease.
Conversely, 30–40% of chronically infected patients progress to
cardiac and/or digestive pathologic involvement [4,5], and
prognostic markers for heart disease progression are required.
A balanced immune response during T. cruzi infection is critical
to control the parasite burden in heart and digestive tissues [6,7].
Production of pro-inflammatory cytokines is required for activa-
tion of the effector T lymphocytes responses and is associated with
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the pathogenesis of Chagas’ disease cardiomyopathy (CC), while
regulatory cytokines (mainly IL-10) are related to protection [8,9].
Peripheral blood mononuclear cells (PBMC) from patients with
CC produce more IFN-c, TNF-a and IL-6, and less IL-4 and IL-
10, compared to individuals with the indeterminate form of the
disease [1,3,7,10–14]. However, other studies failed to demon-
strate any correlation between production of Th1 and Th2
cytokines profile and the clinical stages of Chagas’ disease [15],
being that further investigations to elucidate such mechanisms are
necessary, one aim of this work.
Regulatory T cells (Treg) are an important source of regulatory
cytokines and are involved in the control of the local inflammatory
response and in avoiding extensive tissue destruction. However,
their presence in the site of infections is frequently regarded as an
inducer of parasite persistence [16]. Treg are able to migrate to the
site of cardiac inflammation triggered by T. cruzi, and to suppress
the effector function of CD4 and CD8 T cells during infectious
processes [17]. They suppress the proliferation of effector T cells
(CD4+CD252) when co-cultured, and can also inhibit the
activation of auto-reactive T cells through the expression of co-
inhibitory molecules (CTLA-4) and the production of suppressive
cytokines (IL-10, TGF-b, IL-35) [12,18,19]. Recent studies suggest
that indeterminate Chagas’ disease patients have higher frequency
of CD4+CD25high T cells in comparison to cardiac and non-
infected individuals in their peripheral blood [20,21]. Conse-
quently, the measurement of CD4+CD25high T cells suppressive
activity in patients with indeterminate and cardiac forms of disease
could be an important tool to evaluate a regulatory mechanism
that prevents cardiac damage, which was another aim of this work.
Treg do not seem to play a major role in regulating the effector
responses of CD8 T cells in the myocardium during the acute and
chronic experimental T. cruzi infection, since the blockade of
CD25 did not change the inflammatory response or parasite
burden in mice [13,22,23]. However, the treatment with anti-
GITR resulted in increased mortality, TNF-a production, and
myocarditis with enhanced migration of CD4, CD8, and CCR5
leukocytes to the heart in the T. cruzi infected mice [13]. If Treg
could be involved in the control of immune response and cardiac
disease progression in Chagas’ disease patients is other aim of this
work.
An additional lineage of effector CD4+ T helper lymphocytes,
with potential regulatory properties, produces IL-17A that acts in
several cells types leading the production of GM-CSF, IL-1, IL-6,
and TNF-a, activation of NOS2, metalloproteinases and chemo-
kines, resulting in leukocytes recruitment [24–27]. Treatment of T.
cruzi infected mice with anti-IL-17A mAb lead to increased
myocarditis, premature mortality, and decreased parasite load in
the heart, suggesting that IL-17 controls the host resistance. Also,
IL-17 regulates Th1 cells differentiation, cytokine and chemokine
production and the influx of inflammatory cells to the heart tissue
[28]. IL-17A2/2 mice infected with T. cruzi had a lower survival
rate, multiple organ failure, and sustained parasitemia compared
with wild-type mice, indicating that IL-17A is crucial to leukocyte
activation that are critical for parasite killing [29]. Although it is
not very clear, it seems to be a relationship between Tregs and
Th17 cells. Differentiation of Th17 in the presence of Treg leads
to increased specific cytokine release, what could be due the
consumption of IL-2 [30,31]. Similarly, Treg cell depletion results
in a reduced frequency of IL-17 producers through modulation of
IL-2 [32]. In addition, Treg can also be converted into a variety of
T effector cells, including Th17 cells [33].
The purpose of the present study was to analyze the potential
participation of IL-17 and Treg in the development of different
clinical manifestations of human chronic Chagas’ heart disease.
Our hypothesis was that patients with chronic Chagas’ disease
undergoing cardiomyopathy produce increased levels of IL-17
and have a reduced frequency or suppressive activity of Treg
compared with those patients with the indeterminate form of
the disease. We provide novel information about immunological
mechanisms involved in the human T. cruzi infection that could be
used for the development of chemotherapies, as well as for the
evaluation of prognostic markers of disease.
Methods
Patients
The inclusion of the 39 subjects (10 controls) in our investigation
had the prior approval of an institutional ethics committee
(Hospital das Clı´nicas de Ribeira˜o Preto – USP, Sa˜o Paulo,
Protocol number 2285/2007; Brazil). Signed informed consent
was obtained from all participants. All patients (n = 29) had at least
two positive serology tests for Chagas’ disease, as determined by
ELISA, immunofluorescence or hemagglutination techniques. All
patients underwent a detailed clinical evaluation, 12-lead rest
electrocardiogram (EKG), chest X-ray and a 2D-echocardiogram.
Twenty one patients had not received etiologic treatment and 8
had received full treatment with benznidazole (5 mg/kg/day)
for roughly 60 days. According to their clinical and laboratory
characteristics (Table 1), the chagasic patients were divided in 3
groups: Group 1 (n=10): Patients not treated with benznidazole
and not showing signs of or only having mild cardiomyopathy,
Group 2 (n=11): Patients not treated with benznidazole but
with moderate/severe cardiomyopathy, Group 3 (n=8): Pa-
tients previously treated with benznidazole (cardiomyopathy-free
or mild cardiomyopathy patients). Healthy Individuals from the
same endemic areas were included in this study as controls,
composing the Group 4 (n=10). All of them presented negative
serologic tests for Chagas’ disease and were matched by age and
gender with the Chagas’ disease patients.
T. cruzi antigen
Protein lysate of T. cruzi (Y strain) obtained from LLMCK2
fibroblast cell line was used as the source of antigens. Briefly, the
parasites were harvested, washed and submitted to 6 freeze/thaw
Author Summary
Dilated cardiomyopathy is one of the clinical forms of
Chagas’ disease (CD) after the infection caused by the
parasite Trypanosoma cruzi. Even though strategies
adopted in most Latin-American countries in the last
decades towards vector control have been effective in
reducing the incidence of CD, active transmission is
maintained in some regions, and secondary prevention
approaches are still required for the infected patients,
mostly because the specific anti-parasitic medications are
toxic and perhaps of limited efficacy in chronically infected
individuals. Moreover, there are no markers to predict the
risk of developing dilated cardiomyopathy in asymptom-
atic, chronically infected patients, although the failure in
the mechanisms that control the immune response can be
involved in the development of Chagas’ heart disease. In
this study we show that preserved activity of regulatory T
cells and the production of the cytokine IL-17 are
connected with a more benign evolution of the disease,
which brings a new understanding on the mechanisms
associated with progression of CD.
IL-17, Regulatory T cells and Chagas’ Disease
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cycles in liquid nitrogen and 37uC. The lysate was centrifuged at
12,000 g, the supernatant collected and the protein concentration
determined.
Isolation and culture of PBMC
Peripheral blood was harvested with heparin (50 U/mL) from
healthy individuals and Chagas’ disease patients. PBMC were
isolated using Ficoll-Hypaque (Pharmacia Biotech) density gradi-
ent centrifugation, washed, counted, and used for CD4+CD25+ T
cell isolation or cultured with specific antigen. PBMC (56106
cells/mL) were cultured for 48 h with T. cruzi antigen (10 mg/mL)
and phytohaemagglutinin (PHA) (1 mg/mL) (Sigma-Aldrich, St.
Louis) in 48 wells plates (final volume of 0.5 mL) and labeled with
specific antibodies for phenotypic analysis in flow cytometer and
determination of cytokine production in the supernatant of
PBMC. As the concentration of IL-17 peaked at 48 h culture,
we choose this time point for supernatant collection and cytokine
assay.
Surface markers (CTLA-4, CD103, GITR), Forkhead box P3
(Foxp3) and IL-17 detection
The cultured PBMC were washed in cold phosphate buffered
saline (PBS) and samples of 56105 cells/tube incubated for 30 min
at 4uC with PBS-5% rabbit normal serum to block unspecific
bidding, followed by the addition of 0.5 mg of phycoerythrin (PE),
allophycocyanin (APC) or fluorescein isothiocyanate (FITC)-
labeled antibodies anti-CD3, anti-CD4, anti-CD25, anti-GITR,
anti-CTLA-4 and anti-CD103 (all from BD-Pharmingen) for
additional 30 minutes at 4uC in the dark. To detect the
intracellular expression of Foxp3 the cells were fixed with
cytofix/cytoperm solution (BD Biosciences) for 15 min at room
temperature (RT), washed and stained with anti-Foxp3 or anti-
IL17 peridinin chlorophyll protein (PERCP)-labeled, for 30 min at
4uC in the dark. Subsequently, the cells were washed twice and
suspended in 100 mL of PBS-1% formaldehyde. In the assays
involving intracellular detection of IL-17, the cells were incubated
for additional 6 h in the presence of GolgiStop solution, according
Table 1. Demographic and clinical characteristics of chronic chagasic subjects included in this investigation.
Patient Birth region Gender Age (years) Clinical form LVEF
1 SP Male 47 Cardiomyopathy Free 54%
2 SP Male 52 Cardiomyopathy Free 65%
3 MG Male 59 Cardiomyopathy Free 73%
4 SP Female 53 Mild Cardiomyopathy 68%
5 SP Male 63 Mild Cardiomyopathy 65%
6 GO Female 52 Mild Cardiomyopathy 71%
7 SP Female 63 Mild Cardiomyopathy 54%
8 SP Female 60 Mild Cardiomyopathy 50%
9 GO Male 56 Mild Cardiomyopathy 49%
10 MG Male 42 Mild Cardiomyopathy 57%
11 MG Male 50 Moderate Cardiomyopathy 48%
12 MG Female 57 Moderate Cardiomyopathy 47%
13 SP Female 48 Moderate Cardiomyopathy 39%
14 GO Male 57 Moderate Cardiomyopathy 40%
15 BA Male 40 Moderate Cardiomyopathy 48%
16 SP Female 66 Moderate Cardiomyopathy 49%
17 SP Female 60 Severe Cardiomyopathy 34%
18 MG Female 50 Severe Cardiomyopathy 15%
19 MG Male 50 Severe Cardiomyopathy 32%
20 MG Female 44 Severe Cardiomyopathy 24%
21 SP Male 62 Severe Cardiomyopathy 35%
22* GO F 52 Bz 20 yrs Cardiomyopathy Free 67%
23* GO F 65 Bz 29 yrs Cardiomyopathy Free 61%
24 * GO M 76 Bz 35 yrs Cardiomyopathy Free 64%
25 * GO M 49 Bz 10 yrs Cardiomyopathy Free -
26 * GO F 53 Bz 3 yrs Mild Cardiomyopathy 60%
27 * GO M 79 Bz 28 yrs Mild Cardiomyopathy 70%
28 * GO M 80 Bz 34 yrs Mild Cardiomyopathy 61%
29 * GO F 71 Bz 34 yrs Mild Cardiomyopathy 70%
*Subjects 22, 23, 24, 25, 26, 27, 28 and 29 = with previous etiologic treatment (3 to 35 years ago); Bz = benznidazole.
Cardiomyopathy-free patients: asymptomatic, normal physical examination, normal ECG, normal chest X-rays and normal 2D-echocardiogram. LVEF.50%.
Patients with mild cardiomyopathy : positive symptoms or physical abnormalities, or abnormal ECG and/or chest X-rays and abnormal 2D-echocardiogram but with
preserved global left ventricular function (LVEF.50%); moderate cardiomyopathy : impaired global LV function but EF still .35%; severe cardiomyopathy : LVEF#35%.
doi:10.1371/journal.pntd.0001630.t001
IL-17, Regulatory T cells and Chagas’ Disease
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manufacturer’s recommendations (BD Biosciences) and then
treated as described above.
Flow cytometry acquisition and analysis
Data acquisition was performed using a FACSCanto II (BD)
and the multivariate data analysis performed with the FlowJo
software (Treestar, USA), after collecting 50,000 events/sample.
Distinct gating strategies were used to analyze the regulatory T cell
and IL-17-producing CD4 T cell. Characterization of Treg started
with gating the lymphocytes on FSC versus SSC dot plot. The T-
lymphocyte subpopulations were further selected on FL1 ? anti-
CD4 versus FL2 ? anti-CD25 dot plots. The percentage of cells
expressing CTLA-4, CD-103, GITR and Foxp3 were analyzed in
CD4 T cells, considering three different gates, according to the
level of expression (or not) of CD25. The percentage of cells
expressing intracellular IL-17 was analyzed within the gate of
CD3+CD4+ population.
Cytokine quantification (ELISA)
Cytokine production was assayed in supernatant culture of
PBMC stimulated or not with T. cruzi antigen. ELISA sets were
IL-10, IL-17, IFN-c and TNF-a (R&D, Minneapolis, MN), and
procedures were undertaken according to manufacturers’ instruc-
tions. Optical densities were measured at 450 gm. Results are
expressed as picograms per milliliter.
Co-cultures and CFSE proliferation assays
To verify the regulatory function of CD4+CD25+ T cells
isolated from PBMC of moderate/severe cardiomyopathy or free/
mild cardiomyopathy patients, they were cultured with PBMC
(26105/well) from normal donors, at ratio 1:5 and 1:10, in 96-well
U-bottom plates, in presence of PHA (1 mg/mL), at 37uC and 5%
CO2. CFSE (Molecular Probes) was added at a final concentration
of 1.25 mM. The solution was well mixed and incubated at RT for
5 min. An equal volume of serum was used to quench the reaction,
after which, the cells were washed with PBS with 5% serum. On
day 3 of culture, lymphocytes were collected, washed twice and
suspended in 100 mL of PBS-1% formaldehyde. Data acquisition
was performed using a FACSCanto II and the multivariate data
analysis was performed in the FlowJo software. The data expressed
as percentage of inhibition were calculated based on the PHA-
induced proliferation of allogeneic T cells cultured without
CD4+CD25+ T cells.
Statistical analysis
Statistical analysis was performed using Mann-Whitney or
Kruskal–Wallis tests, performed for the comparison of two or three
variables between groups (INSTAT Software; GraphPad). The
association between IFN-c levels, regulatory T cell activity and left
ventricular ejection fraction were tested by using the Spearman
correlation (INSTAT Software; GraphPad). All values were
considered significantly different at P,0.05.
Results
High frequency of CD4+IL-17+ T cell in PBMC from
cardiomyopathy-free/mild patients
We first aimed to study the ability of cells from patients with
different forms of the disease to produce IL-17, IL-10, IFN-c and
TNF-a after T. cruzi antigen stimuli. Similar levels of IL-17 were
observed in all groups (Figure 1A). In contrast, cells from free/mild
cardiomyopathy patients produced higher amounts of IL-10 than
cells from moderate/severe cardiomyopathy patients group
(Figure 1B). In addition, the response to T. cruzi antigen regarding
the production of TNF-a and IFN-c was higher in patients with
moderate/severe cardiomyopathy (Figure 1C, 1D). The produc-
tion of IL-17 by CD4+ T cells in PBMC from patients belonging to
each experimental group, after being cultured with T. cruzi antigen
obtained from trypomastigotes forms was also assessed using flow
cytometry analysis. CD3+CD4+IL-17+ T cells from free/mild
cardiomyopathy patients (3.73%) displayed increased frequency
when compared to healthy individuals (0.99%). Conversely,
moderate/severe cardiomyopathy patients (1.23%), Bz-treated
Figure 1. Higher IL-10 and lower TNF-a and IFN-c secretion in
free/mild vs. moderate/severe cardiomyopathy patients’
PBMC. Levels of cytokines IL-17 (A), IL-10 (B), TNF-a (C) and IFN-c
(D) as examined by enzyme-linked immunosorbent assay in PBMC
culture supernatants (56106 cells/mL in a 48 plate well) from patients,
after 48 h of antigenic stimulation with trypomastigote antigen (100gg/
well) and independent of the stimuli (Medium). The Chagas’ disease
patients were grouped as: Group 1 (n = 10): Patients not treated with
benznidazole and free/mild cardiomyopathy, group 2 (n = 11): Patients
not treated with benznidazole but with moderate/severe cardiomyop-
athy, group 3 (n = 8): Patients previously treated with benznidazole free/
mild cardiomyopathy. Healthy Individuals (n = 10) from the same
endemic areas were included in this study as controls, composing the
group 4, as described in Materials and Methods. The results are
expressed in picograms per milliliter. Statistical differences are
represented by letters: a and b, P,0.05 (Spearman).
doi:10.1371/journal.pntd.0001630.g001
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patients (1.84%) and healthy individuals had similar frequency of
these cells (representative dot plots are shown in Figure 2A). No
significant differences were found in the intensities of IL-17
expression (MIF) in CD3+CD4+ T cells among the groups of
Chagas’ disease patients. When we analyzed the data obtained with
the patients of all groups, we found that the percentage of CD4+T
cells expressing IL-17 were expressively increased in the cardiomy-
opathy-free/mild group of patients (1.7460.92) compared with all
the other groups. The mean of the percentage of CD4+T cells
expressing IL-17 in moderate/severe cardiomyopathy patients, Bz-
treated patients and healthy individuals were 0.9960.75,
0.9060.58 and 0.6760.57, respectively (Figure 2B). These
findings were confirmed on confocal examination of PBMC.
Patients with different clinical stages of Chagas’ disease
exhibit similar levels of CD4+CD25high T cells
To characterize Treg population, CD4 versus CD25 dot plots
were done and CD25+ lymphocytes classified in low and high or
CD252 T cells (as in Figure 3A). No significant differences in the
frequencies of CD4+CD25high, CD4+CD25low and CD4+CD252
T cells were found among patients presenting different clinical
forms of the disease as well as in controls (P = 0.118 comparing
healthy vs. free/mild cardiomyopathy; P = 0.893, healthy vs.
moderate/severe; P = 0.438, healthy vs. treated; P = 0.109, free/
mild vs. moderate/severe cardiomyopathy; P = 0.247, free/mild
vs. treated; P = 0.494, moderate/severe cardiomyopathy vs.
treated) (Figure 3B, C and D). These results suggest that
assessing the percentage of CD4+CD25+ could not be a reliable
immunological approach to predict the different clinical forms of
Chagas’ disease.
Increased frequencies of CD4+CD25+ T cells expressing
CTLA-4 and Foxp3 in free/mild cardiomyopathy patients
We next determined the frequency of cell that co-express
CD103, GITR, CTLA-4, and Foxp3 on CD4+ T cell expressing
high, low or absence of CD25. Free/mild cardiomyopathy patients
Figure 2. Increased frequency of CD4+IL-17+ Tcells in PBMC from free/mild cardiomyopathy patients. To examine the existence of Th17
lymphocytes in chronic Chagas’ disease patients, PBMC (56106 cells/ml in a 48 plate well) from patients were cultured by 48 h with trypomastigote
antigen (10 mg/mL) and the intracellular expression of IL-17 determined in CD3+CD4+ T cells by flow cytometry. PBMC from control and Chagas’
disease patients in these analyses were gated on lymphocytes via their forward (FSC) and side scatter (SSC) properties, and CD3+CD4+IL-17+ were
analyzed to determine the Th17 population. Representatives flow cytometry analysis of CD3+CD4+IL-17+ T cells gated lymphocytes from, Healthy
individuals, Free/Mild cardiomyopathy patients, Moderate/Severe cardiomyopathy patients and Bz-treated patients are shown in A., while B shows
the grouped analyses of all subjects in each group. Chagas’ disease patients were grouped as: Group 1 (n = 10): Patients not treated with
benznidazole and free/mild cardiomyopathy, group 2 (n = 11): Patients not treated with benznidazole but with moderate/severe cardiomyopathy,
group 3 (n = 8): Patients previously treated with benznidazole free/mild cardiomyopathy. Healthy Individuals (n = 10) from the same endemic areas
were included in this study as controls, composing the group 4, as described in Materials and Methods.
doi:10.1371/journal.pntd.0001630.g002
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presented higher frequency of CD4+CD25high T cells expressing
Foxp3 (P = 0.033) and CTLA-4 (P = 0.042) than moderate/severe
cardiomyopathy patients (Figure 3E). High percentage of
CD4+CD25+Low T cells expressing Foxp3 (P = 0.016) and
CTLA-4 (P = 0.046) were also observed in free/mild cardiomy-
opathy patients compared with moderate severe cardiomyopathy
patients (Figure 3F). Moreover, severe/moderate cardiomyopa-
thy patients showed lower frequency of CD4+CD252 T cells
expressing CTLA-4 (P = 0.035) than free/mild cardiomyopathy
patients, and Bz treated Chagas’ disease patients (Figure 3G).
The mean intensity of fluorescence (MIF) of CTLA-4, CD103,
GITR and Foxp3 was similar in all groups studied. Interestingly,
the expression of CTLA-4, but not CD103, GITR and Foxp3,
in CD4+CD25high T cells was decreased in moderate/severe
cardiomyopathy compared with free/mild cardiomyopathy pa-
tients and health individuals (Figure 4A). These data show that
CTLA-4 expression and frequency of CTL-4+ T cells correlates
with less severe cardiac disease. Moreover, it may indicate that
treatment with benznidazol, with the consequent parasite
elimination, may have important implications in the cardiac
disease progression.
CD4+CD25+ T cells from patients with severe
cardiomyopathy exhibit deficient suppressive activity
We next aimed to study if the reduced frequency of
CD4+CD25+ T cell expressing CTLA-4 and Foxp3 that we found
in severe cardiomyopathy patients correlated with deficient
regulatory activities. CD4+CD25+ T cells from healthy individuals,
free/mild cardiomyopathy patients and severe cardiomyopathy
patients were sorted, and suppressive activity was evaluated in vitro
through co-culture assay with allogeneic T cells stimulated with
PHA. The purity of CD4+CD25+ T cells isolated from free/mild
cardiomyopathy patients and severe cardiomyopathy patients were
about 99%. Interestingly, the inhibitory activity of CD4+CD25+ T
cells from healthy individuals (62.9565.37) (P = 0.0159) and free/
mild cardiomyopathy patients (57.4069.18) (P = 0.0189) were
significantly higher than that observed with CD4+CD25+ T cells
from moderate/severe cardiomyopathy patients (33.7664.67),
Figure 3. Characterization of CD4+CD25+ Treg in patients with different clinical manifestations of Chagas disease. Representative flow
cytometry analysis of CD4+CD25high, CD4+CD25+Low, CD4+CD252 gated lymphocytes is shown in A. PBMC from control and Chagas’ disease patients
in these analyses were gated on lymphocytes via their forward (FSC) and side scatter (SSC) properties, and CD4+CD25high (B), CD4+CD25+Low (C),
CD4+CD252 (D) were performed to determine the regulatory T cell population. CD4+CD25high (E), CD4+CD25+Low (F), CD4+CD252 (G) cells were
analyzed for their expression of membrane CTLA-4, GITR, CD103, and intracellular Foxp3. PBMC (56106 cells/mL in a 48 plate well) from Chagas’
disease patients were cultured with trypomastigote antigen (10 mg/mL) after 48 h of antigenic stimulation the expression of surface markers (CD4,
CD25, CD103, CTLA-4, GITR) and transcriptional factor (Foxp3) were determined. The results are expressed as means 6 standard errors. a and b
indicate statistical differences with P,0.05.
doi:10.1371/journal.pntd.0001630.g003
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when cultured at a ratio of 1:5 Treg:allogeneic T cell (Figure 4B).
Of note, no differences were observed among the groups when the
ratio of Treg:effector was 1:10, possible due to a dilution effect in
suppressive activity of these cells (Figure 4C). The impairment in
suppressive activity observed in CD4+CD25+ T cells from patients
suffering from severe cardiomyopathy correlates with the observa-
tion of reduced amounts of CD4+CD25+ T cells expressing CTLA-4
and Foxp3 in this group of patients.
Increased levels of IFN-c and decreased frequency of
CD4+IL-17+T and deficient regulatory T cell activity
correlates with chronic morbidity from Chagas’ disease
We next correlated LVEF with the levels of IFN-c in the sera of
all Chagas’ disease patients and Treg suppressive activity obtained
after allogeneic cultures (as described). Our results showed that
IFN-c levels during chronic Chagas’ disease are inversely
correlated to the LVEF (P = 0.040, r =20.594) (Figure 5A).
Accordingly, the levels of regulatory T cell activity are directly
correlated with LVEF (P = 0.022, r = 0.500) (Figure 5B). We thus
hypothesized that patients with chronic Chagas’ disease undergo-
ing cardiomyopathy produce increased levels of IL-17 and have a
reduced frequency or suppressive activity of Treg compared with
those patients with the indeterminate form of the disease. To our
surprise, however, we found a positive correlation between
frequency of CD4+IL-17+ T cell and CD4+CD25+HighFoxp3+
(P = 0.042, r = 0.418) (Figure 5C). In addition, no significant
correlation was observed between TNF-a (P = 0.159, r = 0.133),
IL-10 (P = 0.265, r = 0.066) production and LVEF.
Discussion
In this investigation we first evaluated the production of IFN-c,
TNF-a, IL-10 and IL-17 in PBMC obtained from groups of
Chagas’ disease patients and in a group of benznidazol-treated
individuals. The cultures of PBMC from patients with moderate/
severe cardiomyopathy produced higher IFN-c and TNF-a, and
lower IL-10 levels than those observed in PBMC culture from
free/mild cardiomyopathy patients, which is in accordance with
previous reports by other researchers [1,7,9]. An imbalance in the
production of cytokines IFN-c and IL-10 was also observed in the
present study, assaying these cytokines in the sera from chronic
cardiac Chagas’ disease patients: This imbalance has been
implicated in the pathogenesis of Chagas heart disease [1,7,34].
Production of more IFN-c and less IL-10 in cardiac patients
supposedly results in efficient control of parasites replication but
with more lesions to myocardium [5].
In addition, the analysis of IFN-c production by ELISPOT of
CD8 T cells from Chagas’ disease patients showed that the
frequency of IFN-c producing-CD8 T cells is very low among
those patients suffering the most severe form of the disease, and
among individuals living in areas of active transmission of the
disease, indicating that severe Chagas’ cardiomyopathy could be
related with the frequency of IFN-c – producing T cells [31,35].
On the other hand, one study comparing the levels of mRNA
expression for the cytokines IL-5, IL-10, IL-13 and IFN-c in
PBMC from healthy individuals, and patients with cardiomyop-
athy or indeterminate forms of Chagas disease, found no
Figure 4. Patients with severe Chagas’ disease cardiomyopathy
exhibit deficient suppressor activity of Treg. PBMC (56106 cells/
mL in a 48 plate well) from Chagas’ disease patients were cultured with
trypomastigote antigen (10 mg/mL) after 48 h of antigenic stimulation
the mean intensity of fluorescence of CTLA-4 in CD4+CD25high T cells
(A) were performed. Free/Mild cardiomyopathy patients displayed high
levels of CTLA-4 in CD4+CD25high T cells (free/mild cardiomyopathy vs.
moderate/severe P = 0.0352). For functional characterization of
CD4+CD25+ regulatory T cells in Chagas’ disease patients magnetic
bead-sorted CD4+CD25+ T cells purified from PBMC from free/mild
cardiomyopathy patients (n= 5), severe cardiomyopathy (n = 5), and
healthy individuals (n = 5), were tested for their ability to suppress the
proliferation of allogeneic PBMC. The CD4+CD25+ T cells were harvested
and suppressor activity determined as % of proliferation inhibition in
culture from PBMC/CD4+CD25+ T cells 1:5 (B) and 1:10 (C) proportion.
Allogeneic PBMCs (26105 cells/well in a 96 plate well) CFSE stained
were cultured during 72 h with medium only, CD4+CD25+ (26104 and
46104 cells/well, ratio of 1:5), PHA (10 gg/well), PHA plus CD4+CD25+
(ratio of 1:10 and 1:5) from Chagas’ disease patients (free/mild
cardiomyopathy patients and severe cardiomyopathy patients) or
healthy controls. a and b indicate statistical differences with P,0.05
(healthy vs. free/mild cardiomyopathy P = 0.547; healthy patients vs.
moderate/severe P = 0.0159; free/mild cardiomyopathy vs. moderate/
severe P = 0.0189).
doi:10.1371/journal.pntd.0001630.g004
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differences among these groups [11]. Hence, there is not a
consensus regarding the exact participation of classic Th1 cytokine
profiles in the mechanisms that lead to the cardiac lesions during
Chagas’ disease.
It is therefore possible that other cytokine and cellular profiles
participate in the immunological imbalance observed during
Chagas’ disease. One candidate is IL-17 which has effectively been
involved in the control of parasites and in the induction of
myocarditis in T. cruzi experimental infection [24]. In the present
study PBMC from free/mild cardiomyopathy patients exhibited a
higher expression of IL-17 in CD4+ T cells than that observed in
PBMC from patients with severe/moderate cardiomyopathy and
in cells from healthy individuals. Likewise, in the experimental
model the inhibition of IL-17 resulted in enhanced production of
IFN-c and increased cardiac inflammation [24]. Moreover,
impaired activation of immune-related cells that are critical for
the killing of T. cruzi is observed in the absence of IL-17A
gene [25]. Our data confirmed that PBMC from the group of
moderate/severe cardiomyopathy patients produce more IFN-c
and TNF-a and less IL-10 than the cells obtained from the other
groups. Cells from the same group of patients expressed more IL-
17 when cultured with parasite antigens. In the same way, the
infection with the trypanosomatid Leishmania donovani, the etiolog-
ical agent of Kala Azar (KA), stimulates the differentiation into
Th17 cells in PBMC obtained from healthy donors, leading to IL-
17 and IFN-c production [36].
As a result, IL-17 should be important in the control of cardiac
inflammation by playing a negative feedback role on the
production of IFN-c and chemokines during T. cruzi infection in
humans and mice, modulating the cardiac immune-mediated
lesions found in Chagas’ disease patients. Here we showed that
the production of IL-17 is increased in patients without or with
mild cardiac manifestations of the disease, which together with
the results showing efficient suppressive activity of Treg in the
same group of patients, suggest that IL-17 may be involved in
the control of the immune response and, therefore, in the
modulation of cardiac disease progression. As pointed before, IL-
17 is also crucial for the control of parasite growth and host
survival [24,25]. These data are in agreement with that from a
study on a cohort of subjects during a severe outbreak of the
infection by the trypanosomatid L. donovani, in which the analysis
of Th1, Th2, and Th17 cytokine responses by cultured PBMCs
from revealed that IL-17 is associated with protection against
severe KA [32].
The frequency of CD4+CD25+ regulatory T cells among
patients with different clinical forms of Chagas disease was also
examined in the present study. Surprisingly, all groups of patients
showed a similar frequency of CD4+CD25+ T cell and
CD4+CD25high T cells. This is not in agreement with a previous
report showing lower values of CD4+CD25high T cells among
school children with the indeterminate form of Chagas disease
than that values observed in healthy children [17]. However,
the same authors reported later in a study that patients with
the indeterminate form of Chagas’ disease exhibited a higher
frequency of CD4+CD25high T cell expressing Foxp3 and IL-10 as
compared to those individuals with cardiomyopathy [37]. The
last study was confirmed by a recent report showing that
asymptomatic patients had increased amounts of Treg than those
with cardiomyopathy [38]. Thus, it is possible to assume that a
low frequency of regulatory T cell during early stages of Chagas’
heart disease might be associated with the development of more
serious chronic manifestations of Chagas’ heart disease. As
pointed out before, our study does not confirm these data
probably due to our very well characterized groups of patients. All
patients underwent a detailed clinical evaluation, 12-lead rest
electrocardiogram (EKG), chest X-ray and a 2D-echocardio-
gram. However, in the experimental model of Chagas’ disease the
inhibition of Treg function with anti-GITR markedly increased
the parasitemia, myocarditis and mortality compared with
control mice [39].
As we did not detect differences in the percentages of Treg
between the groups of patients in the present study, we
investigated the suppressive activity of these cells. First, we assayed
the expression of surface markers (CD103, CTLA-4 and GITR) as
well as the transcriptional factor Foxp3. A higher expression of
CTLA-4 and Foxp3 in the CD4+CD25high T cells from free/mild
cardiomyopathy patients was observed, when compared to
moderate/severe cardiomyopathy patients. Moreover, the analysis
Figure 5. High Treg activity and reduced levels of IFN-c
correlate with normal LVEF. Correlation analyses were performed
considering the values of LVEF and the levels IFN-c in PBMC culture of
patients (A) or in vitro suppressive activity of Treg (B). In C is showed
the correlation between the frequency of CD4+CD25highFoxp3+ and
CD3+CD4+IL-17+ T cells in PBMC from patients with the different clinical
forms of Chagas’ disease (free/mild cardiomyopathy patients, patients
with moderate/severe cardiomyopathy and chagasic chronic patients
treated with benznidazol after in vitro stimulation with T. cruzi antigens.
The p values as long as the correlation coefficient are shown for each
graph.
doi:10.1371/journal.pntd.0001630.g005
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of CD4+CD25Low cells population demonstrated that free/mild
cardiomyopathy patients and Bz treated patients have a higher
occurrence of CTLA-4 than moderate/severe cardiomyopathy
patients. The high amount of CD4+CD25+ T cells expressing
CTLA-4 and Foxp3 (that activate the regulatory T cell machinery)
in CD4+ CD25+ T cells of free/mild cardiomyopathy and Bz
treated patients may be related to high suppressor activity of these
cells. Furthermore, the greater number of CD4+CD252 T cells of
free/mild cardiomyopathy patients and Bz treated patients
expressing CTLA-4 than cells from moderate/severe cardiomy-
opathy patients, probably contributes to the modulation of
immune response in the heart. A higher incidence of T cells
expressing CTLA-4 among CD4+CD252 T cells from free/mild
cardiomyopathy patients when compared to moderate/severe
cardiomyopathy patients, also suggest a better negative control of
the immune response, since CTLA-4 expression in CD252 T cells
is known to suppress the immune response [40].
The suppressive activity of Treg in PBMC from all groups of
patients herein described was examined based in their capacity to
suppress T cell proliferation. As we suspected, CD4+CD25+ T
cells from Chagas’ disease patients with severe cardiomyopathy
presented reduced capacity to suppress T cell proliferation when
compared to free/mild cardiomyopathy patients and healthy
individuals. This phenomenon may be correlated by low
frequency of CTLA-4 in the CD4+CD252 T cells from cardiac
patients. Nevertheless, it was previously reported that cardiomy-
opathy patients exhibit a higher percentage of CD4+CD25high T
cells expressing CTLA-4 [33]. The mechanism leading to reduced
expression of Foxp3 and CTLA-4 and consequently, deficient
suppressive activity of CD4+CD25+ T cells from patients with
cardiomyopathy has not been elucidated. It is possible that a
defective control of the immune response by Treg/Th17 may
contribute to the pathogenesis of Chagas’ heart disease, in a
similar way as patients with other inflammatory and autoimmune
diseases such as multiple sclerosis, systemic lupus erythematous,
type 1 diabetes, psoriasis and rheumatoid arthritis have compro-
mised functional activity of Treg [41,42].
We also analyzed the levels of cytokines produced by PBMC
from patients after in vitro stimulation with T. cruzi antigens, and we
showed that IFN-c production during chronic Chagas’ disease is
inversely correlated to LVEF, while normal regulatory T cell
activity directly correlates with it. In addition, TNF-a production
levels were lower in free/mild cardiomyopathy patients than in
patients with moderate/severe cardiomyopathy. This finding is in
agreement with a previous study reporting that patients with
significant left ventricular (LV) dysfunction (LV ejection fraction
#50%) showed higher levels of TNF-a, compared to Chagas’
disease patients without LV dysfunction [43]. Moreover, studies in
patients with dilated cardiomyopathy reported a significant
increase of TNF-a among these individuals when compared with
healthy controls, suggesting that the elevation of TNF-a could be
an immune pathogenic mechanism in the progression to
cardiomyopathy. Here we showed that the production of TNF-a
(and not IFN-c) tends to be lower among benznidazole-treated
individuals. Although further research are required to explore the
mechanisms by which benznidazole can induce these differential
effects on cytokines production, these findings has been experi-
mentally addressed before, and coincide with our current results.
For example, it was shown that IFN-c mediates the protective
effect of benznidazole against T. cruzi infection [44], and slightly
inhibits the synthesis of TNF-a in murine cells [45]. The levels
of this cytokine may also constitute an important marker of
ventricular dysfunction in chronic chagasic cardiomyopathy
[46,47].
One import result found in the present study was a positive
correlation between IL-17 and Foxp3 expression in PBMC among
Chagas’ disease patients. Therefore, more IL-17 and Foxp3
expression is preferentially found in free/mild cardiomyopathy
patients. Thus, the expanded Treg are better able to control the
inflammatory response in presence of Th17. This data are in
agreement with the previous demonstration that Th17 are
preferentially differentiated in the presence of Treg [28] due the
consumption of IL-2 by Treg [26,27] Chronic autoimmune
inflammation originates when this process is deregulated, and then
therapeutic intervention becomes necessary to restore that balance
between Th17 and Treg.
It is clear that genetic characteristics of both the host and the
parasite are important in determining the outcome of the
infection. Our data suggest that genetic aspects of the immune
response involved in the functions of Treg, IL-17, and some
related genes may deserve further investigation and may shed light
on the comprehension of the immune pathogenesis of Chagas’
disease.
In summary, our results show that CD4+CD25+ Treg from
patients with severe cardiomyopathy display a deficient suppres-
sive activity, leading to uncontrolled production of pro-inflamma-
tory cytokines (TNF-a and IFN-c) from leukocytes. Moreover,
patients with less aggressive forms of the disease (cardiomyopathy
free or mild cardiomyopathy individuals) produce higher levels of
the cytokines IL-10 and IL-17. Reduced CD4+CD25+ regulatory
T cell function and low levels of IL-17 also correlated with more
advanced cardiomyopathy. We think that these findings may be
helpful in the design of immunotherapeutic approaches for
eventual primary, secondary and tertiary prevention of chronic
Chagas’ cardiomyopathy.
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